What is Delcath Systems?
Headquartered in New York, Delcath Systems operates at the intersection of medical device engineering and oncology. The company is primarily recognized for its development of the Delcath Hepatic CHEMOSAT Delivery System, a sophisticated platform designed to administer high-dose chemotherapy directly to the liver. By isolating the organ from systemic circulation, the technology aims to maximize therapeutic efficacy while minimizing the systemic toxicity typically associated with traditional chemotherapy. This targeted approach addresses a significant unmet need in the treatment of primary and metastatic liver cancers, establishing Delcath as a pivotal entity in the evolution of regional cancer care. The company's long-standing commitment to clinical innovation, dating back to its founding in 1988, has allowed it to navigate the complex regulatory and clinical pathways required to bring specialized oncology solutions to market.
How much funding has Delcath Systems raised?
Delcath Systems has raised a total of $108.5M across 3 funding rounds:
Stock Offering
$7.2M
Other Financing Round
$85M
Series E
$16.3M
Stock Issuance/Offering (2000): $7.2M, investors not publicly disclosed
Other Financing Round (2023): $85M led by BVF Partners, Vivo Capital, and Logos Capital
Series E (2024): $16.3M, investors not publicly disclosed
Key Investors in Delcath Systems
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments with a focus on long-term value creation.
Vivo Capital
Vivo Capital is a global healthcare investment firm headquartered in Palo Alto, managing a diverse portfolio across private and public equity as well as venture capital.
Logos Capital
Logos Capital is an impact-focused investment firm providing financial solutions across sectors including healthcare, with a commitment to sustainable development and international expansion.
What's next for Delcath Systems?
The recent influx of capital is expected to accelerate the company's strategic roadmap, focusing on the expansion of its commercial footprint and the refinement of its delivery systems. As Delcath Systems moves into this next phase of enterprise-level operations, the focus will likely shift toward scaling manufacturing capabilities and broadening the clinical adoption of its melphalan hydrochloride delivery platform. Investors are closely monitoring the company's ability to translate its technological advantages into sustained market share, particularly as it navigates the rigorous demands of the global oncology market. Future growth will be contingent upon successful clinical outcomes and the continued integration of its systems into standard oncology practice, ensuring that the firm remains at the forefront of interventional liver cancer treatment.
See full Delcath Systems company page
